Cardiff Oncology, Inc. Common Stock
CRDFCardiff Oncology, Inc. (CRDF) is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. It specializes in using precision medicine approaches to identify and develop drugs that can improve outcomes for cancer patients, particularly in areas such as non-small cell lung cancer and other solid tumors.
Company News
Cardiff Oncology will participate in the Piper Sandler 37th Annual Healthcare Conference, with CEO Mark Erlander presenting on December 2, 2025, discussing their PLK1 inhibition cancer therapies and lead asset onvansertib.
The KRAS inhibitors market is projected to grow at a 35% CAGR from 2025-2034, driven by rising cancer incidence and a robust pipeline of targeted therapies for KRAS mutations across multiple cancer types.
The global cancer market is projected to surpass $900 billion by 2034, driven by advancements in cancer treatments from biotech companies like Oncolytics Biotech, Exelixis, Cardiff Oncology, ALX Oncology, and Verastem.
Cardiff Oncology, a clinical-stage biotechnology company, announced the pricing of a $40 million underwritten offering of its common stock. The company plans to use the proceeds to fund clinical trials for its lead asset, onvansertib, in metastatic colorectal cancer and pancreatic cancer.
Cardiff Oncology announced positive initial data from a randomized Phase 2 trial evaluating onvansertib in combination with standard-of-care in patients with first-line RAS-mutated metastatic colorectal cancer. The 30mg dose of onvansertib demonstrated a 64% objective response rate, significantly higher than the 33% rate in the control arm.
